|
Successful Entry into the Russian Finished Pharmaceutical Market
2017.11.20
|
|---|
|
Tambutin Tablet are on track to achieve annual sales of 5 billion KRW in Russia.
The export formulation, Tambutin Tablet (Trimebutine Maleate), is a gastrointestinal motility regulator known for its versatile therapeutic effects, including restoring the normal physiological activity of muscles in various parts of the digestive tract. Last year, the product was recognized as an outstanding pharmaceutical at the Russian Pharma Awards, whichs winners based on votes from Russian physicians.
In Russia, Tambutin Tablet will also be featured in a nationwide TV advertising campaign starting in December—an uncommon distinction for over-the-counter medicines—indicating strong brand momentum and projecting over 40% sales growth in the coming year.
Following the success of Tambutin Tablet, Daehan New Pharm has continued to achieve solid performance by completing product registrations for injectable formulations, antibiotics, and oral medications.
Leveraging successful exports to Russia and its robust portfolio of wellness-oriented pharmaceuticals, the company has expanded into Central Asian markets such as Mongolia and Kazakhstan this year. From next year, Daehan New Pharm plans to strengthen its export growth further as product registrations are completed in key Southeast Asian markets, including the Philippines, Taiwan, and Vietnam. |


Home